1/
🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou
@cancerassassin1.bsky.social, presented at #AACR24
thelancet.com/journals/lan...
#oncology #crc
Key findings from this landmark phase 1 trial 🧵:
thelancet.com
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
These results support the safety and potential antitumour activity of inhibiting the
immune checkpoint CISH through the administration of neoantigen-reactive CISH-knockout
TILs, with implications for ...